In (b)(6) 2019, iq, a (b)(6) y/o married, mother of a three y/o child, underwent a minimally invasive robotic hysterectomy for treatment of symptomatic uterine tumors assumed to be benign fibroid disease of (b)(6).
The operating surgeon was (b)(6) from "(b)(6) ob/gyn".
The diagnosis of uterine leiomyosarcoma was pre-operatively missed in this pt.
According to the pt, her surgeon explained that her malignant uterine tumor was morcellated in order to accomplish the small incision robotic hysterectomy operation.
She reports that she was no pre-operatively informed of the need for morcellation and that no discussion took place regarding the possibility that a missed / occult cancer could masquerade as a fibroid tumor and be spread or upstaged by morcellation.
It is unclear whether the surgeon used the robotic equipment as a morcellator to disintegrate the uterine tissues / tumors or if a laparoscopic power morcellator device was used in the operation - and if so, whether a containment bag was used.
Irrespective, the pt underwent morcellation of her cancer despite concerning pre-operative clinical criteria and without having been informed of the potentially deadly risk of cancer upstaging.
Fda safety report id# (b)(4).
|